[1]黃琪峰,鄭琳琳,張 菁.生物信息學分析篩選肺腺癌靶基因及評估預后的價值[J].醫學信息,2019,(22):62-65.[doi:10.3969/j.issn.1006-1959.2019.22.020]
 HUANG Qi-feng,ZHENG Lin-lin,ZHANG Jing.Bioinformatics Analysis of Screening Lung Adenocarcinoma Target Genes and Evaluating Prognostic Value[J].Medical Information,2019,(22):62-65.[doi:10.3969/j.issn.1006-1959.2019.22.020]
點擊復制

生物信息學分析篩選肺腺癌靶基因及評估預后的價值()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年22期
頁碼:
62-65
欄目:
論著
出版日期:
2019-11-15

文章信息/Info

Title:
Bioinformatics Analysis of Screening Lung Adenocarcinoma Target Genes and Evaluating Prognostic Value
文章編號:
1006-1959(2019)22-0062-04
作者:
黃琪峰1鄭琳琳2張 菁1
(浙江大學醫學院附屬邵逸夫醫院藥學部1,超聲科2,浙江 杭州 310000)
Author(s):
HUANG Qi-feng1ZHENG Lin-lin2ZHANG Jing1
(Department of Pharmacy1,Department of Ultrasound2,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou 310000,Zhejiang,China)
關鍵詞:
肺腺癌差異表達基因生物標志物生物信息學分析
Keywords:
Lung adenocarcinomaDifferentially expressed genesBiomarkersBioinformatics analysis
分類號:
R734.2
DOI:
10.3969/j.issn.1006-1959.2019.22.020
文獻標志碼:
A
摘要:
目的 基于生物信息學分析篩選肺腺癌靶基因及評估預后價值。方法 對三個數據集(GSE118370、GSE32863、TCGA-LUAD)分別使用limma和edgeR包篩選出肺腺癌差異表達基因,對共同差異基因進行功能富集分析,通過String數據庫構建蛋白質-蛋白質相互作用(PPI)網絡,采用Cytoscape進行可視化分析并用其插件cytoHubba來篩選關鍵基因,采用Kaplan-Meier曲線進行總體生存分析。結果 共224個共同差異基因,其中上調基因34個,下調基因190個。共同差異基因在血管生成、白細胞調節、免疫反應等生物學過程富集。通過從PPI網絡中篩選出8個關鍵基因,分別為IL6、VWF、PECAM1、SPP1、CDH5、CXCL12、TIMP1、CLDN5。生存分析顯示,PECAM1與LUAD的預后有關。腫瘤組織中PECAM1表達高于正常組織,差異有統計學意義(P<0.05)。結論 PECAM1是一種與肺腺癌預后相關的新的生物標志物,有望成為肺腺癌的一個治療的靶點。
Abstract:
Objective To screen the target genes of lung adenocarcinoma based on bioinformatics analysis and evaluate the prognostic value. Methods Three data sets (GSE118370, GSE32863, TCGA-LUAD) were used to screen differentially expressed genes in lung adenocarcinoma using limma and edgeR packages, functional enrichment analysis of common differential genes, and protein-protein interactions were constructed by String database. PPI) network, using Cytoscape for visual analysis and using its plug-in cytoHubba to screen key genes, Kaplan-Meier curve for overall survival analysis. Results A total of 224 common differential genes, including 34 up-regulated genes and 190 down-regulated genes. Common differential genes are enriched in biological processes such as angiogenesis, leukocyte regulation, and immune response. Eight key genes were screened from the PPI network, namely IL6, VWF, PECAM1, SPP1, CDH5, CXCL12, TIMP1, and CLDN5. Survival analysis showed that PECAM1 was associated with the prognosis of LUAD. The expression of PECAM1 in tumor tissues was higher than that in normal tissues,the difference was statistically significant (P<0.05). Conclusion PECAM1 is a new biomarker related to the prognosis of lung adenocarcinoma and is expected to be a target for the treatment of lung adenocarcinoma.

參考文獻/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. [2]Cho J,Choi SM,Lee J,et al.Proportion and clinical features of never-smokers with non-small cell lung cancer[J].Chin J Cancer,2017,36(1):20. [3]全斌,喻艷林.肺結核合并肺癌的發生機制研究進展[J].山東醫藥,2015,55(24):104-106. [4]Guo T,Ma H,Zhou Y.Bioinformatics analysis of microarray data to identify the candidate biomarkers of lung adenocarcinoma[J].Peer J,2019(7):e7313. [5]Di X,Jin X,Li R,et al.CircRNAs and lung cancer:Biomarkers and master regulators[J].Life Sci,2019(220):177-185. [6]Vargas AJ,Harris CC.Biomarker development in the precision medicine era:lung cancer as a case study[J].Nat Rev Cancer,2016,16(8):525-537. [7]Hanna N,Johnson D,Temin S,et al.Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer:American Society of Clinical Oncology Clinical Practice Guideline Update Summary[J].J Oncol Pract,2017,13(12):832-837. [8]Piao J,Sun J,Yang Y,et al.Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis[J].Gene,2018(647):306-311. [9]高強,鐘英英,丁華杰,等.肺腺癌相關基因的生物信息學分析[J].中國腫瘤生物治療雜志,2019,26(2):190-195. [10]Rask L,Hogdall CK,Kjaer SK,et al.Association of CD31 and p53 With Survival of Ovarian Cancer Patients[J].Anticancer Res,2019,39(2):567-576. [11]Molinsky J,Klánová M,Maswabi B,et al.In vivo growth of mantle cell lymphoma xenografts in immunodeficient mice is positively regulated by VEGF and associated with significant up-regulation of CD31/PECAM1[J].Folia Biol (Praha),2013,59(1):26-31. [12]Mas VR,Maluf DG,Archer KJ,et al.Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma[J].Mol Med,2009,15(3-4):85-94. [13]袁梅琴,王增,王海洋,等.血清PECAM-1和IGF-1水平與晚期胃癌臨床病理特征及預后的相關性研究[J].中華全科醫學,2018(7):1051-1053. [14]Haslinger C,Schweifer N,Stilgenbauer S,et al.Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status[J].J Clin Oncol,2004,22(19):3937-3949. [15]Skrzypczak M,Goryca K,Rubel T,et al.Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability[J].PLoS One,2010,5(10):e13091. [16]Lertkiatmongkol P,Liao D,Mei H,et al.Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31)[J].Curr Opin Hematol,2016,23(3):253-259. [17]Umezawa Y,Akiyama H,Okada K,et al.Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1)[J].J Biol Chem,2017,292(48):19639-19655. [18]Khan I,Bhardwaj M,Shukla S,et al.Carvacrol encapsulated nanocarrier/ nanoemulsion abrogates angiogenesis by downregulating COX-2,VEGF and CD31 in vitro and in vivo in a lung adenocarcinoma model[J].Colloids Surf B Biointerfaces,2019(181):612-622.

相似文獻/References:

[1]劉治利,葛明建.肺部磨玻璃結節的CT特征與治療策略進展[J].醫學信息,2018,(11):49.[doi:10.3969/j.issn.1006-1959.2018.11.016]
 LIU Zhi-li,GE Ming-jian.Advances in CT Features and Treatment Strategies of Pulmonary Ground-glass Nodule[J].Medical Information,2018,(22):49.[doi:10.3969/j.issn.1006-1959.2018.11.016]
[2]彭玉龍,張 露,陳榮輝,等.吉西他濱與培美曲塞聯合卡鉑治療晚期肺腺癌的臨床觀察[J].醫學信息,2018,(11):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
 PENG Yu-long,ZHANG Lu,CHEN Rong-hui,et al.Clinical Observation of Gemcitabine and Pemetrexed Combined with Carboplatin in Treatment of Advanced Lung Adenocarcinoma[J].Medical Information,2018,(22):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
[3]葛麗艷,王 琦,朱 宏,等.基于數據挖掘分析GPR35表達對肺腺癌預后的影響[J].醫學信息,2018,(23):86.[doi:10.3969/j.issn.1006-1959.2018.23.024]
 GE Li-yan,WANG Qi,ZHU Hong,et al.The Effect of GPR35 Expression on Prognosis of Lung Adenocarcinoma was Analyzed Based on Data Mining[J].Medical Information,2018,(22):86.[doi:10.3969/j.issn.1006-1959.2018.23.024]
[4]劉賢豐,李子俊.恩度聯合培美曲塞與順鉑治療晚期肺腺癌的臨床效果觀察[J].醫學信息,2019,(03):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]
 LIU Xian-feng,LI Zi-jun.Clinical Observation of Endo Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma[J].Medical Information,2019,(22):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]

更新日期/Last Update: 2019-11-15
中国足彩网竞彩